Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia
• Main Authors: Germini, Federico, Cossa, Carlo, Trinari, Elisabetta, Iserman, Emma, Ibrahim, Quazi, Pete, Drashti, Keepanasseril, Arun, Page, David, Skinner, Mark W., Iorio, Alfonso
• Format: Journal Article
• Language: English
• Published: England 28.08.2025
• Subjects: haemophilia; CBDR; routine data collection; PRO; PROBE; patient‐reported outcomes
• ISSN: 1351-8216; 1365-2516; 1365-2516
• DOI: 10.1111/hae.70117

The Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire can be used to measure quality of life in persons with haemophilia (PWH) and is integrated in the Canadian Bleeding Disorders Registry (CBDR). This offers the opportunity to compare the same data inputted by patients in PROBE and their treating team in CBDR. Our objectives were to assess the feasibility of collecting PROBE data through CBDR and to compare the data collected from these two sources. We conducted a prospective observational study among PWH using MyCBDR. Participants were invited to digitally complete the PROBE questionnaire at baseline and to repeat it at 6 and 12 months. Additional data were passively collected through CBDR. Data from PROBE and CBDR were compared using Kappa agreement, intraclass correlation (ICC) and Pearson correlation. A total of 142 PWH participated. Recruitment ratios were 21.1% and 12.0% for the two phases. Retention rates were 40.8% at 6 months and 32.4% at 12 months. Three hundred thirteen subjects were involved in the comparison between PROBE and CBDR data. The agreement was good to very good (κ > 0.75) or the correlation very strong, with the exception of the history of inhibitor (κ = 0.57), recent bleeds (κ = 0.48) and current treatment regimen (κ = 0.57). The integration of PROBE with CBDR is feasible and PROBE is a reliable tool for routine PRO data collection. Its use in clinical practice may improve data quality and personalized and patient-centred care.